In July, 2025, GSK (UK) and Hengrui Pharmaceutical (China) executed a $12 billion license and option agreement valued at $12 billion, with $500 million paid upfront.
My friend Alex Wang from PJ Partner in Guangzhou and I recorded a two-part video discussion about this transaction.
Here is the video for Part One:
And Part Two is here:
Contact us to learn more about our ability to search and evaluate licensing opportunities from China!